The effect of combining antitubulin agents on differentiated and undifferentiated human colon cancer cells

Anti-Cancer Drugs

Volumn 9, Issue 3, 1998, Pages 209-221

  Carles, G ^a   Braguer, D ^a   Sabeur, G ^a   Briand, C ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Cell differentiation; Docetaxel; Low concentrations; Paclitaxel; Sequential combination; Vinorelbine

Indexed keywords

DOCETAXEL; NAVELBINE; PACLITAXEL; VINCA ALKALOID;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; COLON CANCER; CYTOTOXICITY; DNA CONTENT; DRUG ANTAGONISM; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; MITOSIS SPINDLE; PRIORITY JOURNAL;

EID: 0031950576     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199803000-00003     Document Type: Article

References (53)

1. Gerzon K. Dimeric Cantaranthus alkaloids. In: Cassady JM, Douros JD, eds. Anticancer agents based on natural products models. New York: Academic Press 1980: 271-317.
2. Dustin P. Microtubules. Berlin: Springer-Verlag, 1984.
3. Manfredi JJ, Horwitz SB. Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther 1984; 25: 83-125.
4. Garcia P, Braguer D, Carles G, et al. Comparative effects of taxol and Taxotere on two different human carcinoma cell lines. Cancer Chemother Pharmacol 1994; 34: 335-43.
5. Wilson L, Jordan MA. Microtubule dynamics taking aim at a moving target. Chem Biol 1995; 2: 569-73.
6. Bhalla K, Ibrado AM, Tourkina E, Tang C, Mahoney M, Huang Y. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 1993; 7: 563-8.
7. Danesi R, Figg W, Reed E, Myers C. Paclitaxel (taxol) inhibits protein isopropylation and induces apoptosis in PC-3 human prostate cancer cells. Mol Pharmacol 1995; 47: 1106-11.
8. Martin SJ, Cotter T. Disruption of microtubules induces an endogenous suicide pathway in human leukemia HL-60 cells. Cell Tissue Kinet 1990; 23: 545-59.
9. Tishler RB, Lamppu DM, Park S, Price B. Microtubuleactivc drugs taxol, vinblastine and nocodazole increase the levels of transcriptionnally active p53. Cancer Res 1995; 55: 6021-5.
10. El Khyari S, Bourgarel V, Barra Y, Braguer D, Briand C. Pretreatment by tubulin agents decreases C-myc induction in human colon carcinoma cell line HT29-D4. Biochem Biophys Res Commun 1997; 231: 751-5.
11. cdc2 coincident with taxol-induced apoptosis. Cell Growth Different 1994; 5: 1041-50.
12. Ilaldar S, Chintapalli J, Croce M. Taxol induces bcl-2 Phosphorylation and death of prostate cancer cells. Cancer Res 1996; 56: 1253-5.
13. Ibrado AM, Liu L, Bhalla K. Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL60 cells. Cancer Res 1997; 57: 1109-15.
14. Hague A, Moorghen M, Hicks D, et al. BCL-2 expression in human colorectal adenomas and carcinomas. Oncogene 1994; 9: 3367-70.
15. Lasorella A, lavarone A, Israel MA. Differentiation of neuroblastoma enhances Bcl-2 expression and induces alterations of apoptosis and drug resistance. Cancer Res 1995; 55: 4711-6.
16. Ding A, Sanchez E, Nathan CF. Taxol shares the ability of bacterial lipopolysaccharide to induce tyrosine phosphorylation of microtubule-associated protein kinase. J Immunol 1993; 151: 559-606.
17. Nishio K, Arioka H, Ishida T. Enhanced interaction between tubulin and microtubule-associated protein 2 via inhibition of MAP kinase and cdc2 kinase by paclitaxel. Int J Cancer 1995; 63: 688-93.
18. Rowinsky EK, Onetto N, Canetta RA. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992; 19: 646-62.
19. Bissery MC, Vrignaud P, Lavelle F. Preclinical profiles of docetaxel (Taxotere): efficacy as a single agent and in combination. Semin Oncol 1995; 22: 3-16.
20. Kano Y, Akutsu M, Tsunoda S, et al. Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer 1996; 74: 704-10.
21. Dieras V, Fumoleau P, Bourgeois H, Misset JL, Azly N, Pouillart P. Taxoids in combination chemotherapy for metastatic breast cancer. Anti-Cancer Drugs 1996; 7: 47-52.
22. Speicher LA, Barone L, Tew KD. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res 1992; 52: 4433-40.
23. Chou TC, Motzer RJ, Tong Y, Bost GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86: 1517-24.
24. Chang AY, DeVore R, Johnson D. Pilot study of vinorelbine (navelbine) and paclitaxel in patients with refractory non-small cell lung cancer. Semin Oncol 1996; 23: 19-21.
25. Photiou A, Shah P, Leong LK, Moss J, Retsas S. In vitro synergy of paclitaxel (Taxol) and vinorelbine (Navelbine) against human melanoma cell lines, Eur J Cancer 1997; 33: 463-70.
26. Knick V, Eberwein D, Miller C. Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells. J Natl Cancer Inst 1995; 87: 1072-7.
27. Michelotti A, Gennari A, Salvadori B, et al. Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: a phase- II study. Ann Oncol 1996; 7: 857-60.
28. Fumoleau P, Delecroix V, Perrocheau G, et al. Final results of a phase I dose finding and pharmacokinetic (PK) study of docetaxel in combination with vinorelbine in metastatic breast cancer. Ann Oncol 1996; 7: 126.
29. Retsas S, Mohith A, Mackenzie H. Taxol and vinorelbine: a new active combination for disseminated malignant melanoma Anti-Cancer Drugs 1996; 7: 161-5.
30. Dimanche-Boitrel MT, Garrido C, Chauffert B. Kinetic resistance to anticancer agents. Cytotechnology 1993; 12: 5596-602.
31. Fantini J, Rognoni JB, Roccabianca M, Pommier G, Marvaldi J. Suramin inhibits cell growth and glycolytic activity and triggers differentiation on human colic adenocarcinoma cell clone HT29-D4. J Biol Chem 1989; 264: 10282-6.
32. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
33. Garcia P, Braguer D, Carles G, Briand C. Simultaneous combination of microtubule depolymerizing and stabilizing agents acts at low doses. Anti-Cancer Drugs 1995; 6: 533-44.
34. Boxdon BJ, Waud WR, Wheeler GP, Hain R, Dansby C, Temple C. Comparison of 1,2-dihydropyrido[3,4-6] pyrazynes (1-deaza-7,8-dihydropteridines) with several other inhibitors of mitosis. Cancer Res 1987; 47: 1621-6.
35. De Ines C, Leynadier D, Barasoain I, et al. Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, and by its chiral isomer, NSC 613863. Cancer Res 1994; 54: 75-84.
36. Debal V, Allam N, Morjani H, et al. Characterization of a navelbine-resistant bladder carcinoma cell line cross-resistant to taxoids. Br J Cancer 1994; 70: 1118-25.
37. 1 phase by interference spindle formation without affecting other microtubule functions during anaphase and telephase. Cancer Res 1994; 54: 4335-61.
38. Jordan MA, Wenkell K, Gardiner S, Derry W, Copp M, Wilson L. Mitotic block induced in Hela cells by low concentrations of Paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996; 56: 816-25.
39. Pepperkok R, Bre MH, Davoust J, Kreis TE. Microtubules are stabilized in confluent epithelial cells but not in fibroblasts. J Cell Biol 1990; 111: 3003-12.
40. Kreis TE. Microtubules containing detyrosinated tubulin are less dynamic. EMBO J 1987; 6: 2597-606.
41. Masson D, Kreis T. Identification and molecular characterization of E-MAP-115, a novel microtubule-associated protein predominantly expressed in epithelial cells J Cell Biol 1993; 133: 357-71.
42. Chapin SJ, Bulinski JC. Cellular microtubules heterogeneous in their content of microtubule-associated protein 4 (MAP4). Cell Motil Cytosk 1994; 27: 133-49.
43. Dumontet C, Duran GE, Steger KA, et al. Differential expression of tubulin isotypes during the cell cycle. Cell Motil Cytosk 1996; 35: 49-58.
44. . Kavallaris M, Kuo D, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific-tubulin isotypes. J Clin Invest 1997; 100: 1282-93.
45. Blagosklonny MV, Giannakakou P, El-Deiry WS, et al. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 1997; 57: 130-5.
46. L protein content in HT29 cells. Oncogene 1996; 13: 2631-7.
47. L overexpression inhibits taxol-induced Yama protease activity and apoptosis. Cell Growth Different 1996; 7: 1087-94.
48. Krajewski S, Krajewska M, Shabaik A, et al. Immunohistochemical analysis of in vivo patterns of Bcl-x expression. Cancer Res 1994; 54: 5501-7.
49. Moss SF, Agarwal B, Arber N, et al. Increased intestinal Bak expression results in apoptosis. Biochem Biophys Res Commun 1996; 223: 199-203.
50. Debernadis D, Siré EG, De Feudis P, et al. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 1997; 57: 870-4.
51. Schwartz B, Lamprecht SA, Polak-Charcon S, Niv Y, Kim YS. Induction of the differentiated phenotype in human colon cancer cells is associated with the attenuation of subcellular tyrosine phosphorylation. Oncol Res 1995; 7: 277-87.
52. Davis PK, Dudek SM, Johnson GV. Select alterations in protein kinases and phosphatases during apoptosis of differentiated PC12 cells. J Neurochem 1997; 68: 2338-47.
53. Muggia FM. Clinical activity in other tumors. In: McGuire WP, Rowinsky EK, eds. Paclitaxel in cancer treatment. New York: Marcel Dekker 1995: 329-37.